Form 4: Castle Biosciences COO Sells Shares Under 10b5-1 Plan

Castle Biosciences COO Kristen M. Oelschlager reported the sale of 8,186 shares of common stock for approximately $24.40 per share and 400 shares for approximately $24.78 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences, Inc., reported transactions involving the sale of company stock.
• On July 1, 2026, 8,186 shares of common stock were sold at a weighted-average price of $24.40 per share, totaling approximately $199,774.40.
• An additional 400 shares of common stock were sold at a weighted-average price of $24.78 per share, totaling approximately $9,912.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2026.
• Following these transactions, Oelschlager beneficially owns 22,274 shares directly and 97,251 shares indirectly through The Fritz Shorter Trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the sale of shares by a key executive, despite the transaction being conducted under a pre-arranged 10b5-1 plan.

Negatives

• The Chief Operating Officer sold a significant number of shares, which could be perceived negatively by the market.

Risks

• The sale of shares by a key executive could signal a lack of confidence in the company's future performance, although the sale was conducted under a pre-arranged 10b5-1 plan.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider sales, even under Rule 10b5-1 plans, are closely watched by investors as they can sometimes precede significant price movements. The context of the broader biotech market and Castle Biosciences' specific product pipeline would be crucial for a complete assessment.

Related Party Transactions

• The Fritz Shorter Trust, of which the Reporting Person and her spouse are trustees and beneficiaries, holds 97,251 shares indirectly.

Stakeholder Impact

• Shareholders: May view the sale by a COO with some concern, though the 10b5-1 plan mitigates insider trading concerns.
• Employees: May interpret the sale as a signal from management.
• Management: The COO is diversifying or managing personal finances through this sale.

Next Steps

• The reporting person will continue to hold shares beneficially owned after the reported transactions.

Key Dates

Recommendation

The sale was executed under a Rule 10b5-1 plan, indicating it was pre-arranged and not necessarily a reflection of current negative sentiment. The remaining beneficial ownership is substantial. Therefore, a 'hold' recommendation is appropriate pending further company performance updates.

Keywords

Castle Biosciences, CSTL, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Executive Compensation, Beneficial Ownership